Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Tivic Health Systems ( (TIVC) ) has shared an announcement.
On June 25, 2025, Tivic Health Systems announced the completion of the Optimization Study for its non-invasive cervical vagus nerve stimulation (ncVNS) device. Conducted by The Feinstein Institute of Bioelectronic Medicine, the study aimed to identify optimal device parameters for influencing autonomic nervous system function. Initial findings highlight the importance of personalization for therapeutic efficacy, and the results are expected to be released later this year. This development positions Tivic Health to potentially create highly differentiated treatments for large patient populations with unmet clinical needs, amidst a growing global market for vagus nerve stimulation.
Spark’s Take on TIVC Stock
According to Spark, TipRanks’ AI Analyst, TIVC is a Neutral.
The overall stock score of 43 reflects Tivic Health Systems’ current financial difficulties, including declining revenues and negative profitability. However, recent strategic initiatives and corporate events provide some optimism for future growth. The stock’s technical indicators and valuation remain weak, necessitating significant improvements in financial performance and market sentiment to enhance stock attractiveness.
To see Spark’s full report on TIVC stock, click here.
More about Tivic Health Systems
Tivic Health Systems, Inc. is a diversified immunotherapeutics company focused on developing treatments that stimulate immune pathways to address disease. The company is involved in both biochemical and bioelectric therapies, with a particular emphasis on non-invasive medical devices that personalize stimulation to modulate pathways implicated in prevalent and debilitating diseases. Tivic’s lead biopharma product candidate, Entolimod, has received Fast Track and Orphan Drug designation by the FDA, and its first FDA-approved product, ClearUP, treats sinus pain and pressure.
Average Trading Volume: 1,274,169
Technical Sentiment Signal: Sell
Current Market Cap: $3.74M
For an in-depth examination of TIVC stock, go to TipRanks’ Overview page.